Dr. Daniel Gonzalez, DC · Evidence review

Peptides: the honest guide.

Some peptides are among the best-studied medicines of the decade. Others have hundreds of rat studies and almost no human data. Here is what the research actually supports, what it does not, and where the real risks hide.

~30people in every published human study of BPC-157, combined. No randomized trial has been run.
41 to 71%of gray-market peptide samples failed basic quality standards in a 2026 analysis.
20%fewer heart attacks, strokes and cardiac deaths on semaglutide in the SELECT trial.
6unapproved peptides HHS moved to let pharmacies compound in an October 2026 draft policy.
Start here

What a peptide actually is

A peptide is a short chain of amino acids, the same building blocks as protein. Your body makes thousands of them. Insulin is a peptide. So are oxytocin and GLP-1, the hormone behind today’s weight loss drugs.

That is why the word “peptide” tells you almost nothing about safety or results. The category includes FDA-approved drugs with outcome trials in tens of thousands of people, and it includes vials sold online as “research only” that may not contain what the label says.

So judge each one on its own evidence. A weak claim about a peptide does not mean the peptide is useless, and a strong drug does not make every peptide strong.

The molecule is not the marketing. Ask what has been shown in humans, for the use you care about, made by a source you can verify.
How to read this page

The evidence ladder

Every peptide below gets a rating for how much human evidence supports it. Animal and cell studies matter, but most results in rats never hold up in people.

Strong human evidence

Large randomized trials, FDA review, years of real-world safety data.

Solid but limited

Real human trials, but narrower uses, approval outside the US, or not yet approved.

Small human studies

A few small or short trials. Promising signals, unknown long-term safety.

Mostly animal data

Lab and animal research. Little or no controlled human data.

The most common peptides

Pros and cons, one by one

Semaglutide

FDA-approved

Ozempic, Wegovy, Rybelsus
Strong human evidence

A GLP-1 receptor agonist. It slows stomach emptying and turns down appetite signals in the brain.

Pros

  • About 15% average weight loss over 68 weeks in the STEP-1 trial
  • 20% fewer major cardiac events in people with heart disease (SELECT)
  • Decades of GLP-1 drug safety data

Cons

  • Nausea and constipation are common
  • Up to about 40% of weight lost can be lean mass without strength training and protein
  • Most people regain much of the weight after stopping
  • Compounded copies are now restricted

Tirzepatide

FDA-approved

Mounjaro, Zepbound
Strong human evidence

A dual GIP and GLP-1 agonist. It acts on two gut hormone pathways instead of one.

Pros

  • About 21% average weight loss at the top dose over 72 weeks (SURMOUNT-1)
  • Large improvements in blood sugar and A1c
  • Also approved for obstructive sleep apnea with obesity

Cons

  • Same GI side effects and lean mass concerns as semaglutide
  • Long-term use is likely needed to keep results
  • Expensive without coverage
  • Shortage ended, so mass compounding is no longer allowed

Retatrutide

Investigational

LY3437943, the “triple agonist”
Solid but limited

Acts on GIP, GLP-1 and glucagon receptors at once. Eli Lilly plans to file for FDA approval in early 2027.

Pros

  • Phase 3 trials report some of the largest drug-driven weight loss ever measured
  • Thousands of people studied in controlled trials

Cons

  • Not approved. Anything sold today is gray market
  • Long-term safety still unknown
  • Heart rate increases were seen in earlier trials
  • No approved reference product to check quality against

BPC-157

HHS draft policy

“Body Protection Compound”
Mostly animal data

A 15 amino acid fragment of a protein found in stomach juice. The most hyped healing peptide on the internet.

Pros

  • Hundreds of animal studies show faster tendon, ligament, muscle and gut healing
  • Small human pilots reported no serious side effects
  • Now eligible for compounding as a single ingredient under the Oct 2026 HHS draft

Cons

  • Only three small, uncontrolled human studies exist
  • Not FDA-approved. FDA scientists raised immune reaction and impurity concerns
  • Promotes new blood vessel growth, a theoretical worry around cancer
  • Banned in tested sports

TB-500

HHS draft policy

Thymosin beta-4 fragment
Mostly animal data

A short synthetic piece of thymosin beta-4, a protein involved in cell movement and tissue repair.

Pros

  • Animal studies support wound and tissue repair
  • Often paired with BPC-157 for injury recovery

Cons

  • FDA reviewers found no human safety studies
  • Many vials labeled “TB-500” actually contain the full 43 amino acid protein, a different molecule
  • Blends like BPC-157 plus TB-500 are not covered by the HHS policy
  • Banned in tested sports

GHK-Cu

Not approved as a drug

Copper peptide
Small human studies

A copper-binding peptide your blood naturally contains. Levels fall with age. Widely used in skin care.

Pros

  • Topical studies show better skin firmness and fewer fine lines
  • Long safety record in cosmetics
  • Inexpensive in serum form

Cons

  • Injectable use has very little human data
  • Injectable form was on the FDA safety-concern list until its nomination was withdrawn in 2026
  • Not included in the HHS compounding policy

CJC-1295 + Ipamorelin

Unapproved

Growth hormone secretagogue stack
Small human studies

Two peptides that signal the pituitary to release more of your own growth hormone. Popular for body composition and sleep.

Pros

  • Early human studies show raised growth hormone and IGF-1
  • Works through your own pituitary instead of replacing hormone

Cons

  • No long-term outcome trials for fat loss, muscle or aging
  • Chronically high IGF-1 carries open questions about blood sugar and cancer risk
  • Not approved and not covered by the HHS policy
  • Banned in tested sports

Sermorelin

Formerly approved

GHRH 1-29
Small human studies

The first 29 amino acids of growth hormone releasing hormone. Once FDA-approved for children with growth failure.

Pros

  • Long clinical history and a known safety profile
  • Pulled from market in 2008 for business reasons, not safety
  • Keeps the body’s natural growth hormone rhythm

Cons

  • Modest effects in healthy adults
  • Little evidence for anti-aging claims
  • Daily injections, and compounded quality varies

Tesamorelin

FDA-approved

Egrifta
Strong (approved use)

A growth hormone releasing hormone analog approved to reduce excess belly fat in people with HIV-related lipodystrophy.

Pros

  • Randomized trials show about 15% less visceral fat in six months
  • Also lowered liver fat in trials
  • Pharmaceutical-grade product

Cons

  • Approved only for one population
  • Fat tends to return after stopping
  • Can raise blood sugar and IGF-1
  • Costly

MOTS-c

HHS draft policy

Mitochondrial-derived peptide
Mostly animal data

A peptide coded in mitochondrial DNA. Your levels rise naturally with exercise.

Pros

  • Mouse studies show better insulin sensitivity and exercise capacity
  • Interesting biology linking mitochondria and metabolism

Cons

  • FDA reviewers found no human safety studies
  • No human outcome data at all
  • Exercise already raises it for free

Epitalon

HHS draft policy

Epithalon, AEDG
Mostly animal data

A four amino acid peptide from Russian research on the pineal gland, marketed for telomeres and longevity.

Pros

  • Cell and animal studies on telomerase and lifespan
  • Some older Russian studies in elderly people

Cons

  • Most research comes from one group and has not been independently replicated
  • FDA reviewers found no human safety studies
  • Longevity claims far outrun the data

Semax

HHS draft policy

ACTH 4-10 analog, nasal spray
Small human studies

A nasal peptide used in Russia for stroke recovery and cognition. Marketed in the US for focus and memory.

Pros

  • Decades of clinical use in Russia
  • Some human data in stroke recovery
  • Nasal route, no injection

Cons

  • Very few rigorous trials published in Western journals
  • Little data in healthy people looking for a “focus boost”
  • Covered by the HHS policy as a nasal product only

KPV

HHS draft policy

Alpha-MSH fragment
Mostly animal data

A three amino acid piece of an anti-inflammatory hormone. Marketed for gut inflammation and skin.

Pros

  • Animal colitis models show reduced inflammation
  • Oral and topical forms, no injection required

Cons

  • HHS itself cited an absence of human information
  • No controlled trials in people with IBD or skin disease

PT-141

FDA-approved

Bremelanotide, Vyleesi
Strong (approved use)

Acts on melanocortin receptors in the brain. Approved in 2019 for low sexual desire in premenopausal women.

Pros

  • Randomized phase 3 trials behind the approval
  • Works on desire in the brain, not blood flow
  • Taken only as needed

Cons

  • Nausea in about 40% of trial participants
  • Temporary rise in blood pressure
  • Skin darkening with repeated use
  • Modest average benefit; less data in men

Thymosin Alpha-1

Approved abroad

Zadaxin
Solid but limited

An immune-signaling peptide from the thymus. Approved in dozens of countries for hepatitis and as an immune support.

Pros

  • Real human trials outside the US
  • Generally well tolerated in those trials

Cons

  • Not FDA-approved
  • Not covered by the HHS compounding policy
  • Evidence is for specific diseases, not general “immune boosting”

Collagen Peptides

Food supplement

Hydrolyzed collagen
Solid but limited

The peptide most people already take. A powder made by breaking collagen into small fragments.

Pros

  • Pooled trials show modest gains in skin hydration and elasticity
  • Some data for joint discomfort
  • It is food. Very safe and cheap

Cons

  • Many trials are industry funded
  • Lacks tryptophan, so it is not a complete protein
  • Effects are small compared with the marketing
Where it comes from matters

Same name, three very different products

The source can matter as much as the molecule. Here is how the three ways people get peptides compare.

Tier 1

FDA-approved drug

  • Made and tested under FDA standards
  • Dose and contents are what the label says
  • Known side effects and outcome data
  • Cost and insurance hurdles
  • Only a handful of peptides qualify
Tier 2

Compounded by a licensed pharmacy

  • Requires a prescription and a licensed pharmacy
  • Under the Oct 2026 HHS draft, each lot needs a certificate of analysis from an FDA-registered manufacturer
  • Adverse events must be reported
  • Compounded drugs are never FDA-reviewed for safety or results
  • Only six peptides covered, one per product, no blends
Tier 3

“Research use only” online

  • Cheap and easy to buy
  • Illegal to sell for human use
  • In one 2026 test, none of four vials contained the labeled peptide
  • About 15% of tested samples carried bacterial endotoxin
  • No prescriber, no monitoring, no recourse
Before you start any peptide

Five questions worth answering first

Is there human evidence for my goal?

Not for the molecule in general. For the specific outcome you want, in people like you.

Can I verify the source?

Ask for a lot-specific test from the actual batch. A generic certificate on a website is not proof.

Are the basics handled?

Sleep, protein, strength training, daylight and stress. No peptide outperforms a broken foundation.

What labs will we track?

Depending on the peptide: glucose, A1c, IGF-1, lipids, kidney and liver markers, blood pressure.

What is the exit plan?

Know what happens when you stop, and how long you plan to stay on it before you start.

Sources

  1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). NEJM 2021
  2. Wilding JPH, et al. Weight regain after withdrawal of semaglutide (STEP-1 extension). Diabetes Obes Metab 2022
  3. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). NEJM 2023
  4. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022
  5. Eli Lilly. Topline results from TRIUMPH-2 and TRIUMPH-3; planned BLA Q1 2027. July 2026
  6. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. 2025
  7. Pharmacy Times. Heal or harm: BPC-157 in the gray zone. July 2026
  8. HHS. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Federal Register, Oct 2026
  9. FDA. Pharmacy Compounding Advisory Committee, July 23 to 24, 2026. FDA.gov
  10. Arnold & Porter. HHS draft enforcement discretion policy on compounded peptides. Nov 2026
  11. Orrick. FDA moves to shut the door on large-scale compounding of GLP-1 drugs. May 2026
  12. Mendias CL, et al. Quality of gray-market peptides. Sports Medicine, 2026.
  13. Falutz J, et al. Metabolic effects of a growth hormone releasing factor in HIV patients with abdominal fat. NEJM 2007
  14. Kingsberg SA, et al. Bremelanotide for hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019
  15. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide. Int J Mol Sci 2018
  16. de Miranda RB, et al. Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis. Int J Dermatol 2021

This page is for education only and is not medical advice. Do not start, stop or change any medication or peptide without a licensed clinician who knows your history. Regulatory status reviewed November 10, 2026; the HHS peptide policy is a draft and may change.